Loading companies…
Loading companies…
United States · Biotech · Healthtech
Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions
| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series A+ | $45M | ArrowMark Partners — Role not disclosedJanus Henderson Investors — Role not disclosedRA Capital — Role not disclosedSR One — Role not disclosedVida Ventures — Role not disclosed | |
| Series A | $50M | Platanus — Role not disclosedSR One — Role not disclosedVida Ventures — Role not disclosed |